In the last trading session, 2.12 million Taysha Gene Therapies Inc (NASDAQ:TSHA) shares changed hands as the company’s beta touched 0.88. With the company’s per share price at $1.70 changed hands at $0.05 or 3.03% during last session, the market valuation stood at $348.41M. TSHA’s last price was a discount, traded about -154.12% off its 52-week high of $4.32. The share price had its 52-week low at $1.19, which suggests the last value was 30.0% up since then.
Analysts gave the Taysha Gene Therapies Inc (TSHA) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.09. If we narrow down to specifics, the data shows that 0 out of 8 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 1 recommended TSHA as a Hold, 7 felt it is a Buy and 0 rated the stock as Underweight. Taysha Gene Therapies Inc’s EPS for the current quarter is expected to be 0.
Taysha Gene Therapies Inc (NASDAQ:TSHA) trade information
Instantly TSHA was in green as seen at the end of in last trading. With action 6.25%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -1.73%, with the 5-day performance at 6.25% in the green. However, in the 30-day time frame, Taysha Gene Therapies Inc (NASDAQ:TSHA) is 11.84% up.
The consensus price target for the stock as assigned by Wall Street analysts is 8.5, meaning bulls need an upside of 80.0% from its current market value. According to analyst projections, TSHA’s forecast low is 5 with 44 as the target high. To hit the forecast high, the stock’s price needs a -2488.24% plunge from its current level, while the stock would need to soar -194.12% for it to hit the projected low.
Taysha Gene Therapies Inc (TSHA) estimates and forecasts
Year-over-year growth is forecast to reach -46.63% down from the last financial year.
Consensus estimates given by 11 financial analysts project the company’s revenue in the current quarter to hit an average of 2.05M. 8 analysts are of the opinion that Taysha Gene Therapies Inc’s revenue for the current quarter will be 1.49M. The company’s revenue for the corresponding quarters a year ago was 3.6M and 3.41M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -43.04%. The estimates for the next quarter sales put growth at -56.25%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -137.69%. The 2025 estimates are for Taysha Gene Therapies Inc earnings to increase by 61.44%, but the outlook for the next 5-year period is at 30.94% per year.
TSHA Dividends
Taysha Gene Therapies Inc is expected to release its next quarterly earnings report in March.
RTW INVESTMENTS, LP holds the second largest percentage of outstanding shares, with 8.075% or 18.8 million shares worth $42.11 million as of 2024-06-30.
Among Mutual Funds, the top two as of Nov 30, 2024 were iShares Russell 2000 ETF and Vanguard Total Stock Market Index Fund . With 4.84 shares estimated at $8.23 million under it, the former controlled 2.36% of total outstanding shares. On the other hand, Vanguard Total Stock Market Index Fund held about 2.17% of the shares, roughly 4.46 shares worth around $7.58 million.
